Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
BUSINESS
Sawai Follows Fuso to Challenge Remitch Patent Ruling
Sawai Pharmaceutical on June 9 appealed to Japan’s Supreme Court to overturn a high court ruling in a patent suit over its generic version of Remitch OD Tablets (nalfurafine) - a move that comes days after a similar challenge made…
To read the full story
Related Article
- Fuso Takes Remitch Patent Case to Top Court
June 9, 2025
- Sawai Cuts FY2024 Results after Remitch Ruling, Net Profit Drops by Half
June 4, 2025
- Fuso Sets Up 8 Billion Yen Credit Line after Remitch Ruling
June 3, 2025
- Sawai, Fuso Ordered to Pay 20-Plus Billion Yen in Remitch Patent Suit
May 29, 2025
- Fuso Says Toray Jacked Up Damage Claim in Remitch Patent Suit
March 28, 2024
- Extension of Use Patent Term for Remitch Affirmed: Toray
October 27, 2021
- Toray Sues Sawai, Fuso over Use Patent for Remitch OD Tablets
December 20, 2018
BUSINESS
- RaQualia Expands Alliance with HK inno.N, Licenses Japan Rights to Reflux Therapy
December 15, 2025
- Obesity Market Projected at 46.6 Billion Yen by 2040 as GLP-1s Fuel Growth: Fuji Keizai
December 15, 2025
- Roche Diagnostics Taps Ex-Medtronic Japan VP Maeda as New CEO
December 15, 2025
- Chugai to Launch US Partnering Office in January 2026
December 15, 2025
- Scrap “Spillover,” “Special” Rules If G1 Rule Is Applied Early: Chugai CEO
December 15, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…